Newscast – Page 59 – media

Syncona Once More Proves Commitment to Freeline in Series B Funding Round

Syncona has once again proven its commitment to gene therapy start-up, Freeline Therapeutics with a £85 million investment from the £88 million series B funding round. Freeline’s main focus is on gene therapy for Haemophilia B and Farby disease and this latest cash injection ensures Syncosa’s majority stake in the startup.
- Source: Fierce Biotech
- 657
- June 20, 2018
biotech Company Insight funding hemophilia
RapidSOS and Apple Partner to Help with Emergency Location Identification

In 2015, Apple initiated HELO (Hybridized Emergency Location) a protocol that helps identify a callers’ location using various data such as wifi access points, GPS and cell phone towers. This has now been further developed by RapidSOS to send the data via secure channels to emergency call rooms.
- Source: drugdu
- 635
- June 20, 2018
Apple Company Insight digital health
Identification of Asthma Causative Agent – Rhinovirus

The rhinovirus, otherwise known as the cold virus, is considered as the causative agent of asthma. Nearly 80% of all asthma attacks are caused by this cold virus, of which children are mostly affected. This viral asthma leads to chronic lung disease which in turn could be life-threatening.
- Source: India Times
- 847
- June 20, 2018
asthma cold virus Researches
AuriGen Aims to Raise Funds for Development of Irregular Heartbeat Device

Chief executive Dr. John Thompson, stated that the company also plans on targeting angel investors and a number of high-net-worth individuals in the new funding round. According to another report, AuriGen won a €2.5m funding boost from the EU-backed Horizon 2020 SME funding scheme amidst a lot of competition just last week.
- Source: The Independent
- 628
- June 19, 2018
Company Insight funding medical device medtech
Heart Risk to be Detected by CRISPR

A new risk assessment tool combining gene editing technology CRISPR-Cas9 with stem cells using disease modeling techniques has been developed by a team of scientists at the Stanford University Cardiovascular Institute. The tool has facilitated the modeling of individual patients’ heart in a lab and enabled undertaking of tests to ascertain whether or not signs of diseases are displayed by cardiac cells, as per a statement by the American Heart Association.
- Source: Fierce Biotech
- 661
- June 19, 2018
American Heart Association CRISPR-Cas9 Researches
Spider Silk to Boost Your Immunity

A team of scientists from different universities across Europe has developed an innovative method of delivering vaccines directly to the white blood cells in order to boost the immune system against life-threatening diseases. They have devised a tough microcapsule using synthetic spider silk that can deliver vaccines directly to T-cells.
- Source: MedicalNewsToday
- 656
- June 19, 2018
Researches vaccines
Water Fluoridation Prevents Dental Decay

With sufficient evidence, it was proved that community water fluoridation would provide proper dental health benefits for children and adolescents in the U.S. It is this advised to start consuming fluoridated drinking water as early as possible, anywhere between the ages of 2-8 years.
- Source: ScienceDaily
- 561
- June 19, 2018
health tips Researches
Precision Medicine – An Ultimate Panacea

Precision medicine is an emerging approach for disease treatment where genes, the environment and lifestyle of each person is taken into account.
- Source: FierceHealthcare
- 586
- June 19, 2018
DNA precision medicine Researches
Increased Liver Disease Survival Rate by Telementoring

This rural telehealth consultation program named Specialty Care Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO) was launched by the Department of Veterans Affairs in New Mexico in 2012. To begin with, this program was used for chronic liver disease. This consultation connected rural care teams to specialty clinics, where the patients can be treated in a better way.
- Source: drugdu
- 694
- June 19, 2018
liver disease Researches Telemedicine
Sarepta Therapeutics and Brammer Bio Partnership to Develop Gene Therapy

Biopharma Sarepta Therapeutics and Brammer Bio enter into a long-term strategic partnership to design and develop new manufacturing facilities at CDMO’s plant in Massachusetts. The new partnership is for the development of the production of its microdystrophin, Duchenne Muscular Dystrophy (DMD) therapy and future gene therapies.
- Source: FiercePharma
- 609
- June 18, 2018
Company Insight DMD Gene therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.